WO2000062816A3 - Genetic tolerization - Google Patents

Genetic tolerization Download PDF

Info

Publication number
WO2000062816A3
WO2000062816A3 PCT/US2000/010099 US0010099W WO0062816A3 WO 2000062816 A3 WO2000062816 A3 WO 2000062816A3 US 0010099 W US0010099 W US 0010099W WO 0062816 A3 WO0062816 A3 WO 0062816A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
methods
tolerizing
vaccines
genetic
Prior art date
Application number
PCT/US2000/010099
Other languages
French (fr)
Other versions
WO2000062816A2 (en
Inventor
Stephen Albert Johnston
Baoxi Qu
Original Assignee
Univ Texas
Stephen Albert Johnston
Baoxi Qu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Stephen Albert Johnston, Baoxi Qu filed Critical Univ Texas
Priority to AU42436/00A priority Critical patent/AU4243600A/en
Publication of WO2000062816A2 publication Critical patent/WO2000062816A2/en
Publication of WO2000062816A3 publication Critical patent/WO2000062816A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Abstract

The present invention provides methods for the administration of genetic vaccines to promote or induce a greater tolerance to various antigens. This will permit the treatment of patients with an allergy or autoimmunity, asthma and other immunomodulatory diseases where an undesired immune response to one or more antigens exists. In addition, methods of designing tolerizing vaccines, including methods for identifying nucleic acids that encode tolerizing antigens and cell-type specific regulatory nucleic acid sequences, are provided.
PCT/US2000/010099 1999-04-15 2000-04-15 Genetic tolerization WO2000062816A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42436/00A AU4243600A (en) 1999-04-15 2000-04-15 Genetic tolerization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12975399P 1999-04-15 1999-04-15
US60/129,753 1999-04-15

Publications (2)

Publication Number Publication Date
WO2000062816A2 WO2000062816A2 (en) 2000-10-26
WO2000062816A3 true WO2000062816A3 (en) 2001-02-08

Family

ID=22441444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010099 WO2000062816A2 (en) 1999-04-15 2000-04-15 Genetic tolerization

Country Status (2)

Country Link
AU (1) AU4243600A (en)
WO (1) WO2000062816A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (en) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Secretable forms of alkaline phosphatase
WO1993009815A1 (en) * 1991-11-22 1993-05-27 The General Hospital Corporation Specific tolerance in transplantation
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (en) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Secretable forms of alkaline phosphatase
WO1993009815A1 (en) * 1991-11-22 1993-05-27 The General Hospital Corporation Specific tolerance in transplantation
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EVANS GREGORY L ET AL: "Genetic induction of immune tolerance to factor VIII in a murine model for hemophilia A.", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology;San Diego, California, USA; December 5-9, 1997, pages 240A, XP002151727, ISSN: 0006-4971 *
MARSHALL DEBORAH J ET AL: "Manipulation of the immune response by foreign gene expression in the thymus.", LEUKEMIA (BASINGSTOKE), vol. 9, no. SUPPL. 1, 1995, pages S128 - S132, XP000953427, ISSN: 0887-6924 *
SCHUMACHER INGO K ET AL: "Use of gene therapy to suppress the antigen-specific immune responses in mice to an HLA antigen.", TRANSPLANTATION (BALTIMORE), vol. 62, no. 6, 1996, pages 831 - 836, XP000953428, ISSN: 0041-1337 *
WANG XIAOMING ET AL: "Transgenic studies with a keratin promoter-driven growth hormone transgene: Prospects for gene therapy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 1, 1997, 1997, pages 219 - 226, XP002152286, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU4243600A (en) 2000-11-02
WO2000062816A2 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EP1363660A4 (en) Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation
WO2004013172A3 (en) Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2000073430A3 (en) Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
WO2003059385A3 (en) Hiv vaccine and method of use
WO2003090687A3 (en) Using heat shock proteins to increase immune response
DE69732029D1 (en) DNA-Containing VACCINES
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2002064757A3 (en) Influenza viruses with enhanced transcriptional and replicational capacities
MXPA02005506A (en) Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens.
WO2002029074A3 (en) Genetic immunisation against cervical carcinoma
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
WO2003031569A3 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2000062816A3 (en) Genetic tolerization
WO2001003728A3 (en) Gene therapy for enhancing and/or inducing angiogenesis
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO2001049325A3 (en) Gene therapy to promote angiogenesis and/or the treatment of heart failure
WO2000073432A3 (en) Activation of dendritic cells to enhance immunity
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP